Key result
Intraperitoneal monovalent FSTL3-Fc fusion protein increases systemic muscle mass in mice.
Why the study?
Monovalent FSTL3-Fc fusion protein overcomes limitations of current anti-myostatin therapies, motivating a facile protocol for its affinity purification and in vivo validation.
This protocol provides a facile method for producing and validating mono-FSTL3-Fc, a novel fusion protein that increases systemic muscle mass in mice.
Answers are grounded in this paper and cite their sources.
Facilitates preclinical testing of mono-FSTL3-Fc; leaves open translation to human muscle disorders.
Follistatin-like 3 (FSTL3) is an endogenous antagonist against transforming growth factor-β family ligands. Monovalent FSTL3-Fc fusion protein (mono-FSTL3-Fc) generated with knobs-into-holes technology overcomes limitations of current anti-myostatin therapies. We have developed a facile protocol for affinity purification of the Fc-fused protein from the supernatant of HEK293T cells stably expressing the protein. This protocol is advantageous by only requiring readily accessible equipment. We further outline the steps for validation of mono-FSTL3-Fc increasing systemic muscle mass in mice after intraperitoneal administration. For complete details on the use and execution of this protocol, please refer to Ozawa et al. (2021).
No takes yet. Share an insight, caveat, or question.
Ozawa et al. (2021) studied this question. Monovalent FSTL3-Fc fusion protein (mono-FSTL3-Fc) was evaluated on Systemic muscle mass. A protocol was developed for the affinity purification of monovalent FSTL3-Fc fusion protein and its validation for increasing systemic muscle mass in mice after intraperitoneal administration.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: